The State of California has filed suit against drug maker AbbVie, alleging that the company provided kickbacks to healthcare providers throughout the state to encourage them to prescribe its brand-name adalimumab, Humira, and used a network of registered nurses to mislead patients about the risks associated with the drug.
The State of California has filed suit against drug maker AbbVie, alleging that the company provided kickbacks to healthcare providers throughout the state to encourage them to prescribe its brand-name adalimumab, Humira, and used a network of registered nurses to mislead patients about the risks associated with the drug.
According to the heavily redacted lawsuit, AbbVie engaged in a “classic” kickback scheme by offering prescribers cash, meals, drinks, trips, and patient referrals. It also provided physicians with valuable goods and services, such as insurance and prior authorization processing, as well as practice management hardware and software.
The lawsuit centers on AbbVie’s use of a network of registered nurses, called Ambassadors, who visited patients in their homes. These nurses trained patients on administering their subcutaneous injections and provided patient care, paperwork help, and other services, all of which alleviated burdens on prescribers’ practices in exchange for selecting Humira from a range of available treatments.
However, says the suit, these nurses were explicitly trained by AbbVie to downplay the risks of taking Humira, which carries black box warnings for serious adverse events (AEs), such as malignancy. The Ambassadors were also trained to avoid answering any questions about AEs by offering to help patients get their Humira for under $5 per dose.
Also included in the lawsuit are allegations that AbbVie used its employees to suggest that patients take higher doses of Humira than are FDA approved in order to sell more of the drug.
AbbVie’s alleged scheme was brought to light by Lazaro Suarez, a registered nurse in Florida, who worked for AbbVie via a subcontractor, QuintilesIMS (now IQVIA), as a nurse educator and patient ambassador between 2013 and 2014. According to the suit, Suarez became aware of the nationwide reach of AbbVie’s nurse network because his success as an Ambassador led him to a role as a trainer of other staff.
While Suarez initially took the job as an Ambassador to help care for patients with challenging diagnoses, says the suit, he later “…felt that the focus of the Ambassador program was getting and keeping patients on Humira to maintain and increase AbbVie’s profits.”
The State of California has demanded a jury trial, and is seeking injunctive relief, assessments of 3 times the amount of each claim for compensation for insurance contracts on Humira, and civil penalties of $10,000 for each fraudulent claim presented to an insurance company.
This is not the first occasion on which AbbVie has been accused of using unfair means to increase its profits on its top-selling product. In August, the Initiative for Medicines, Access, and Knowledge, a public interest group, released a report that called AbbVie “the worst patent offender” in the pharmaceutical landscape for forging a patent estate around Humira while raising the drug’s price by 144% since 2012. Furthermore, given AbbVie’s settlements with biosimilar developers that will not allow a biosimilar adalimumab to reach US patients prior to 2023, US lawmakers have called on the Federal Trade Commission to investigate whether AbbVie’s settlements are lawful.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.